BidaskClub upgraded shares of Intra-Cellular Therapies (NASDAQ:ITCI) from a strong sell rating to a sell rating in a research note issued to investors on Thursday, December 21st.
A number of other brokerages also recently weighed in on ITCI. Cowen reissued an outperform rating and set a $27.00 price target (up previously from $20.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. BTIG Research reissued a buy rating and set a $36.00 price target on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. SunTrust Banks reaffirmed a hold rating and issued a $22.00 target price (up previously from $16.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. Piper Jaffray Companies raised Intra-Cellular Therapies from a neutral rating to an overweight rating and upped their target price for the company from $14.00 to $33.00 in a research report on Thursday, September 7th. Finally, ValuEngine downgraded Intra-Cellular Therapies from a sell rating to a strong sell rating in a research report on Wednesday, September 27th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $25.56.
Intra-Cellular Therapies (NASDAQ:ITCI) traded up $0.47 during trading hours on Thursday, reaching $18.87. The company’s stock had a trading volume of 435,257 shares, compared to its average volume of 660,678. Intra-Cellular Therapies has a 1 year low of $7.85 and a 1 year high of $22.67. The firm has a market capitalization of $1,040.00, a PE ratio of -8.62 and a beta of 0.72.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.06 million. During the same quarter in the prior year, the company posted ($0.70) earnings per share. Intra-Cellular Therapies’s revenue was up 675.0% on a year-over-year basis. equities analysts predict that Intra-Cellular Therapies will post -2.13 earnings per share for the current year.
In other Intra-Cellular Therapies news, Chairman Sharon Mates sold 6,604 shares of the company’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $17.48, for a total transaction of $115,437.92. Following the completion of the sale, the chairman now directly owns 1,088,707 shares in the company, valued at $19,030,598.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Lawrence J. Hineline sold 3,192 shares of the stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $15.67, for a total value of $50,018.64. Following the completion of the transaction, the chief financial officer now owns 68,686 shares of the company’s stock, valued at $1,076,309.62. The disclosure for this sale can be found here. Insiders have sold 49,410 shares of company stock valued at $802,481 over the last 90 days. Corporate insiders own 21.00% of the company’s stock.
A number of large investors have recently made changes to their positions in ITCI. Perceptive Advisors LLC bought a new position in Intra-Cellular Therapies during the 3rd quarter worth $14,667,000. Wasatch Advisors Inc. raised its position in Intra-Cellular Therapies by 65.1% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock worth $20,611,000 after purchasing an additional 654,400 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Intra-Cellular Therapies during the 3rd quarter worth $8,663,000. Dimensional Fund Advisors LP raised its position in Intra-Cellular Therapies by 419.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock worth $8,038,000 after purchasing an additional 522,565 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Intra-Cellular Therapies by 336.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after purchasing an additional 447,586 shares during the last quarter. 74.47% of the stock is owned by institutional investors and hedge funds.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.